Bausch Health Companies Inc. (TSE:BHC – Free Report) – Equities research analysts at Zacks Research lifted their Q2 2026 earnings per share (EPS) estimates for Bausch Health Companies in a research note issued on Friday, July 24th. Zacks Research analyst Team now anticipates that the company will post earnings of $1.35 per share for the quarter, up from their prior estimate of $1.31. The consensus estimate for Bausch Health Companies’ current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q4 2026 earnings at $1.62 EPS, FY2026 earnings at $5.54 EPS and Q1 2027 earnings at $1.13 EPS.
Bausch Health Companies (TSE:BHC – Get Free Report) last announced its earnings results on Wednesday, April 29th. The company reported C$1.08 earnings per share (EPS) for the quarter. The firm had revenue of C$3.51 billion during the quarter. Bausch Health Companies had a positive return on equity of 120.43% and a negative net margin of 13.54%.
Bausch Health Companies Trading Up 1.4%
BHC opened at C$6.34 on Monday. The company has a quick ratio of 0.58, a current ratio of 1.32 and a debt-to-equity ratio of -1,009.96. Bausch Health Companies has a 52 week low of C$6.10 and a 52 week high of C$11.97. The business’s 50 day moving average is C$7.00 and its two-hundred day moving average is C$7.63. The firm has a market cap of C$2.37 billion, a price-to-earnings ratio of -1.96, a price-to-earnings-growth ratio of 0.21 and a beta of 0.97.
Bausch Health Companies Company Profile
Bausch Health Companies Inc (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.
Further Reading
- Five stocks we like better than Bausch Health Companies
- AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
- Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now
- Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?
- Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.
